HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CP 609754 (CP 609,754)

a farnesyltransferase inhibitor; structure in first source

Also Known As:

CP 609,754; CP-609,754; CP-609754

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - CP 609754: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        CP 609754: 1

Experts

1.	Bartkowski, Lisa Michele: 1 article (11/2004)
2.	Ferrante, Karen J: 1 article (11/2004)
3.	Kajiji, Shama M: 1 article (11/2004)
4.	Langevin, Michael: 1 article (11/2004)
5.	Lush, Richard: 1 article (11/2004)
6.	Mahany, John J: 1 article (11/2004)
7.	Moulder, Stacy L: 1 article (11/2004)
8.	Noe, Dennis A: 1 article (11/2004)
9.	Paillet, Simone: 1 article (11/2004)
10.	Rocha-Lima, Caio: 1 article (11/2004)

Related Diseases

1.

Neoplasms (Cancer)

11/01/2004 - "A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors."
11/01/2004 - "The purpose of this phase I clinical trial was to determine the maximum-tolerated dose and toxicity of CP-609,754 in patients with solid tumors refractory to standard therapies, to determine the cellular effects of CP-609,754 on its molecular target (farnesyltransferase), and to determine the recommended phase II dose (RP2D) of this agent. "

Related Drugs and Biologics

1.	Farnesyltranstransferase (Farnesyltransferase)

Related Therapies and Procedures

1.	Therapeutics